Department of Pharmacology

October 29, 2015

Inflammation, obesity and diabetes

Vanderbilt study adds to the mounting role for inflammatory signaling in obesity.

By Leigh MacMillan
October 2, 2015

The yin and yang of COX-2

New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs.

By Sanjay Mishra
October 1, 2015

Collaboration seeks to develop new therapies for bone, other diseases

La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.

By Leigh MacMillan
August 13, 2015

VUMC study shifts thinking on how bone fractures heal

New findings show that fibrin, a protein that was thought to play a key role in fracture healing, is not required, shifting understanding of how fractures heal.

By Leigh MacMillan
August 7, 2015

Bridging the antibiotic gap

Vanderbilt researchers have discovered how certain molecules with antibiotic properties are synthesized, findings that could lead to new drugs that overcome the increased antibiotic resistance in bacteria.

By Sanjay Mishra and Bill Snyder
July 24, 2015

How to trick a wily virus

Vanderbilt investigators have discovered how human antibodies induced during testing of an experimental “bird flu” vaccine kill the virus.

By Sanjay Mishra
June 17, 2015

Lit up COX-2 cancer probe

A new imaging probe developed by Vanderbilt investigators enhances tumor visibility and has broad applications in diagnosing and monitoring patients with cancer.
By Henry H. Ong
June 12, 2015

New strategy to combat HIV

Inhibitors of the enzyme phospholipase D1 suppress the replication of HIV-1, Vanderbilt investigators have discovered.
By Bill Snyder
May 7, 2015

Findings reveal new target in quest to ease schizophrenia

Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.
By Bill Snyder
May 6, 2015

Neurofibromin fine-tunes bone growth

The protein neurofibromin acts as a brake in a signaling pathway that is important in bone development, Vanderbilt researchers have discovered.
By Leigh MacMillan
April 23, 2015

Lecture explores efforts to move pharmacogenetics into the clinic

Preemptive genotyping: It sounds like a surprise attack, and it is.
By Bill Snyder
April 3, 2015

Cancer signaling pathway blocker

Researchers at Vanderbilt University have discovered a new way to inhibit Hedgehog (Hh) signaling, an important regulatory pathway for vertebrate development – and cancer.
By VUMC News and Communications
April 2, 2015

Pharmacogenomics expert set for Wilkinson Lecture

Mary Relling, Pharm.D., chair of the Department of Pharmaceutical Sciences at St. Jude Children’s Research Hospital in Memphis, will deliver this year’s Grant R. Wilkinson Distinguished Lecture in Clinical Pharmacology on Thursday, April 9.
By Bill Snyder
1 … 8 9 10 11 12 … 14